Team:UCSF
From 2010.igem.org
(→Project Description) |
|||
(9 intermediate revisions not shown) | |||
Line 6: | Line 6: | ||
{{Template:UCSF/BannerAndNav}} | {{Template:UCSF/BannerAndNav}} | ||
{{Template:UCSF/LeftStart}} | {{Template:UCSF/LeftStart}} | ||
+ | <br> | ||
===Project Description=== | ===Project Description=== | ||
- | + | Killer cells of the immune system identify cancer and pathogen-infected cells and kill them. These potent killers travel throughout the body, recognizing proteins and other molecules on the surface of cells. In order to differentiate between healthy and diseased cells, killer cells use a variety of receptors, which bind to specific ligands on the target cells’ surface. If the target cell is deemed potentially dangerous, the killer cell grips the target cell tightly and creates an immunological synapse at the site of adhesion. Within this immunological synapse, the killer cell releases cytotoxic granules to kill the target cell without harming nearby cells, triggering a directed apoptotic response. | |
- | Our team will focus on improving | + | Our team will focus on improving killer cells’ specificity and killing efficiency towards cancerous target cells. By using tools of synthetic biology, we hope to create powerful killing bio-machines to fight cancer. Our newly engineered synthetic devices would have the potential to enhance current adoptive cell-based immunotherapy for cancer patients. |
+ | <br> | ||
<html> | <html> | ||
Line 20: | Line 22: | ||
<a href="https://2010.igem.org/Team:UCSF/Project/Arsenal" ><img src="https://static.igem.org/mediawiki/2010/3/35/UCSF_arsenal_home_icon.png" border="0" width="208" alt="Better Arsenal" /> | <a href="https://2010.igem.org/Team:UCSF/Project/Arsenal" ><img src="https://static.igem.org/mediawiki/2010/3/35/UCSF_arsenal_home_icon.png" border="0" width="208" alt="Better Arsenal" /> | ||
</a> | </a> | ||
+ | <br><br> | ||
+ | |||
</html> | </html> | ||
{{Template:UCSF/LeftEnd}} | {{Template:UCSF/LeftEnd}} | ||
{{Template:UCSF/RightStart}} | {{Template:UCSF/RightStart}} | ||
<html> | <html> | ||
- | <h3 style="color: | + | <br><br> |
+ | <h3 style="color:black;">TEAM</h3> | ||
<div align="center"> | <div align="center"> | ||
<a href="https://2010.igem.org/Team:UCSF/Team"><img src="https://static.igem.org/mediawiki/2010/f/ff/Team_photo.png" /></a> | <a href="https://2010.igem.org/Team:UCSF/Team"><img src="https://static.igem.org/mediawiki/2010/f/ff/Team_photo.png" /></a> | ||
Line 30: | Line 35: | ||
<br><br> | <br><br> | ||
- | <h3 style="color: | + | <h3 style="color:black;">SPONSORS</h3> |
<div align="center"> | <div align="center"> | ||
<a href="https://2010.igem.org/Team:UCSF/Sponsors"><img src="https://static.igem.org/mediawiki/2010/3/38/Sponsors_2010.png" width="200px" /></a> | <a href="https://2010.igem.org/Team:UCSF/Sponsors"><img src="https://static.igem.org/mediawiki/2010/3/38/Sponsors_2010.png" width="200px" /></a> | ||
</div> | </div> | ||
+ | |||
+ | <br><br> | ||
+ | <h5 style="color:black;">Follow us on <a href="http://twitter.com/#!/iGEM_UCSF">Twitter!</a></h5> | ||
</html> | </html> | ||
Latest revision as of 22:27, 15 November 2010
Project DescriptionKiller cells of the immune system identify cancer and pathogen-infected cells and kill them. These potent killers travel throughout the body, recognizing proteins and other molecules on the surface of cells. In order to differentiate between healthy and diseased cells, killer cells use a variety of receptors, which bind to specific ligands on the target cells’ surface. If the target cell is deemed potentially dangerous, the killer cell grips the target cell tightly and creates an immunological synapse at the site of adhesion. Within this immunological synapse, the killer cell releases cytotoxic granules to kill the target cell without harming nearby cells, triggering a directed apoptotic response. Our team will focus on improving killer cells’ specificity and killing efficiency towards cancerous target cells. By using tools of synthetic biology, we hope to create powerful killing bio-machines to fight cancer. Our newly engineered synthetic devices would have the potential to enhance current adoptive cell-based immunotherapy for cancer patients.
|